Fosamax (Alendronate) and Osteonecrosis of the Jaw: Understanding the FDA Warning and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge, particularly regarding common medications and their intended benefits. Within this legacy framework, audiences were accustomed to receiving information about drugs like bisphosphonates in the context of bone health maintenance and disease prevention. The transition from this generalized health education to a more targeted risk awareness requires a careful shift in focus—from population-level benefits to individual exposure considerations. As the therapeutic landscape evolves, so too must the public’s understanding of potential adverse outcomes associated with long-term pharmaceutical use. Specifically, the widespread prescription of Fosamax (alendronate) for osteoporosis management has introduced a new dimension of concern: the possibility of osteonecrosis of the jaw (ONJ) as a rare but serious complication. This pivot moves the discussion from abstract health promotion to concrete exposure scenarios, where patients and clinicians alike must weigh therapeutic necessity against emerging safety signals. The bridge between general health literacy and clinical vigilance lies in recognizing that medication exposure carries inherent risk profiles that demand informed awareness.

Bridging General Health Science to Fosamax-Specific Risks

The legacy of general health science now converges with a more focused inquiry into the specific circumstances under which bisphosphonate exposure may elevate the risk of jaw bone complications. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Osteonecrosis of the Jaw: Clinical Evidence and Risk Factors

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Risk Assessment Tools

Mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast activity, reducing bone turnover. The jawbone has unique structural and metabolic characteristics that may make it particularly susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the jawbone's response to bisphosphonates differs from other skeletal sites, potentially explaining the localized occurrence of ONJ. Risk assessment tools are being developed to better predict ONJ risk. One study introduced the concepts of equivalent dose (ED) and threshold dose (TD) as predictive risk assessment tools for medication-related osteonecrosis of the jaw (MRONJ) (https://pubmed.ncbi.nlm.nih.gov/40619534/). In this study, ED for each medication was standardized to the cumulative dose of four years of weekly oral alendronate use (14,560 mg) (https://pubmed.ncbi.nlm.nih.gov/40619534/). This approach may help clinicians identify patients at higher risk for developing ONJ based on cumulative bisphosphonate exposure.

FDA Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the FDA-approved labeling. The prescribing information includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings describe the condition, associated risk factors, and recommendations for management, including consideration of treatment discontinuation before invasive dental procedures. For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and ONJ development, as well as the presence of other risk factors. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge with the same or another bisphosphonate supports a causal relationship in some patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the similar incidence of symptoms in placebo groups in clinical trials indicates that not all cases are attributable to the drug.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning regarding Fosamax and osteonecrosis of the jaw?

The FDA-approved labeling for Fosamax includes a specific warning under 'Warnings and Precautions' about osteonecrosis of the jaw (ONJ). The warning describes ONJ as a condition of exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection, and notes that it has been reported in patients taking bisphosphonates including Fosamax. The labeling also lists risk factors such as invasive dental procedures, cancer diagnosis, concomitant therapies, and poor oral hygiene, and recommends consideration of treatment discontinuation before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits osteoclast activity, reducing bone turnover. The jawbone has unique structural and metabolic characteristics that may make it particularly susceptible to bisphosphonate-related complications. Research suggests that the jawbone's response to bisphosphonates differs from other skeletal sites, potentially explaining the localized occurrence of ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with duration of bisphosphonate exposure.

What is the typical timeline for developing ONJ after starting Fosamax?

The time to onset of symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.